If a supplied lot fails agreed specifications, we’ll replace it at no cost or refund its purchase price in full.
Quality test failed? Free replacement or full refund.
Off-spec? Free replacement or full refund.
FDA PCAC reviews 7 peptides for the 503A bulks list (BPC-157, KPV, TB-500, MOTs-C, Emideltide, Semax, Epitalon). Read our compounder's decision tree. Read our briefing →
FDA PCAC reviews 7 peptides for the 503A bulks list in July. Read →
FDA PCAC: 7 peptides under review. Read →
GHRH 1-29 fragment
Batch documentation
Ask sales for the Sermorelin COA matched to the offered batch. Review the recorded tests, specifications, and results against your QA and destination-market requirements before quotation.
Overview
Sermorelin is the unmodified 29-residue N-terminal fragment of native human GHRH (residues 1-29). The fragment retains the full receptor-binding activity of the parent 44-residue molecule, which is why Sermorelin became the historical reference compound against which every engineered GHRH analogue (CJC-1295, Tesamorelin, Modified GRF 1-29) has subsequently been benchmarked. Serum half-life is limited to roughly 10-12 minutes by DPP-4 cleavage at the Tyr1-Ala2 bond, and that exact PK constraint is what drove the subsequent design work behind the CJC-1295 family's substitution chemistry. Sermorelin itself was previously approved as a prescription drug (Geref) for paediatric GH-deficiency diagnostic use. Vialdyne releases Sermorelin acetate as a lyophilised powder against a ≥99.0% main-peak HPLC specification. The 29-residue length sits well within reliable SPPS range, and every released lot comes with its batch COA covering RP-HPLC peak integration and ESI-MS identity; Karl Fischer water and counter-ion quantitation are available on request and listed on the COA when tested. In compounding-pharmacy practice, Sermorelin fits two niches: pulsatile-pattern GH-axis preparations where the short half-life is the right tool (the rapid clearance preserves natural GH pulse architecture), and short-acting clinical compounding where sustained elevation is undesirable. For sustained-action profiles, the CJC-1295 with DAC SKU is the appropriate alternative.
Applications & buyer fit
GH-axis peptides ship to two main buyer types: compounding pharmacies dispensing under physician supervision, and research labs studying somatotropic-axis pharmacology. Pharmacies typically want sterile-filled vials with the full release packet (sterility, endotoxin, CCI); labs typically want loose-format lyophilized powder with sequence verification. Blends (the CJC-1295 / Ipamorelin combination is the canonical example) are usually co-lyophilized rather than solution-mixed for potency stability.
Sourced for
Buyer fit
Documentation that ships
Procurement note: For sterile-filled vials, confirm whether sterility, endotoxin, and CCI are included in the agreed release packet. For loose lyophilized powder, request the batch COA and separately scope any sequence-level evidence required by the buyer's written procedure.
Primary buyer fit: academic and contract research laboratories and 503A / 503B compounding pharmacies.
Specifications
Nasal spray listing · US inventory
Sermorelin is also listed in this catalog as a nasal spray solution.

Capsule listing
Sermorelin is also listed as a capsule product, dispatched within the United States from US inventory.

Batch COAs and test reports
Each picture is a low-resolution preview of a report's first page, with batch and report numbers covered. For the full, clear report, ask our sales team, naming the product and strength.
Batch COASermorelin 2 mg
HPLC purity · MS identity
Batch COA
Full, clear copy from sales
Batch COASermorelin 5 mg
HPLC purity · MS identity
Batch COA
Full, clear copy from sales
Batch COASermorelin 10 mg
HPLC purity · MS identity
Batch COA
Full, clear copy from sales
Independent test fails? Full refund. How it works
Browse all COAs and reportsRegulatory note
Sold as a pharmaceutical-grade active for research and for compounding-pharmacy formulation where local regulations permit (notably 503A / 503B in the United States and analogous regimes elsewhere). Not a finished dosage form. Sterile-filled vials are available with full release documentation; the buyer is responsible for verifying scheduling and dispense requirements in the destination market.
Selected literature
Frequently asked questions
The unmodified GHRH(1-29) fragment behaves like the rest of the GH-axis class in the freezer: keep the sealed lyophilised vial at -20 C, protected from moisture, and it sits under a 24-month re-test schedule with the specific date documented on the released-batch certificate. Once reconstituted in bacteriostatic water, sub-divide into single-use aliquots at once and treat freeze-thaw count, not slow temperature drift, as the dominant driver of measured-potency loss. Capping cumulative thaws at three or fewer per aliquot is the operational rule that keeps assayed potency inside specification through the working period.
Identity rests on ESI-MS at the expected fragment mass plus RP-HPLC main-peak integration; sequence confirmation by peptide-mapping or amino-acid analysis is available on request to round out the identity package. Because this is a native, unprotected sequence, the chromatogram is also your degradation window: methionine oxidation and N-terminal truncation appear as resolved satellite peaks, so a receiving pharmacy can read chemical stability directly off the same trace. Request water content and counter-ion quantitation on the certificate as well, since they govern the net-peptide mass used when converting a labelled fill into a dispensed amount.
Yes. Sermorelin is listed as a nasal spray solution (2 mg), filled in 10 mL or 20 mL bottles, with an MOQ of 10 bottles per content and fill. It is dispatched within the United States from US inventory; send an inquiry for current availability.
Send any vial from your order to an independent laboratory of your choice. If the report shows the product does not meet the specification on its COA — purity below the stated minimum, or an identity that does not match — share the report with our sales team and we refund that product in full.
Related peptides
Modified GRF 1-29 · GHRH analog
Nasal spray listed
Ghrelin / GHSR pathway GH-release peptide
Nasal spray listed
57-mer
GHRH analog · approved for HIV-associated lipodystrophy
Nasal spray listed